SEC Filing Summary: Form 6-K
Business Context and Reporting Period
Company: Galapagos NV (Note: The filing metadata references Lakefront Biotherapeutics NV, but the document text explicitly identifies the registrant as Galapagos NV).
Reporting Period: May 2023 (Specifically May 4, 2023).
Filing Type: Form 6-K (Report of Foreign Private Issuer).
Purpose: To distribute a press release dated May 4, 2023, which is attached as Exhibit 99.1 and incorporated by reference into the company's Registration Statements on Form S-8.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely as a conduit for a press release and does not contain a financial statement or quantitative data within the provided text.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. The content is limited to the administrative incorporation of a press release.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. While the press release (Exhibit 99.1) is referenced, its specific content is not included in the provided text, except for a note that quotes from Dr. Paul Stoffels and Bart Filius are excluded from incorporation by reference into Form S-8 statements.
Investor Verification Checklist
- Verify the actual content of the press release dated May 4, 2023 (Exhibit 99.1), as the summary text does not contain the announcement details.
- Confirm the correct registrant name (Galapagos NV) versus the metadata label (Lakefront Biotherapeutics NV).
- Review the specific quotes from Dr. Paul Stoffels and Bart Filius separately, as they are explicitly excluded from the incorporation by reference into Form S-8.
- Check the referenced Form S-8 Registration Statements (File Nos. 333-204567 through 333-268756) for the full context of the incorporated information.